Reviewer's report
Title:Long-term Follow up Helicobacter Pylori Reinfection Rate After
Second-Line Treatment: Bismuth-Containing Quadruple Therapy versus
Moxifloxacin-Based Triple Therapy
Version: 2Date:14 June 2013
Reviewer: Arne Kandulski
Reviewer's report:
SUMMARY
This is a prospective trial that randomized patients after failed first line H. pylori
eradication to receive either bismuth containing quadruple therapy (EBMT) or
moxifloxacin-based second line regimen (MEA).
After initial successful eradication within the first year, patients´ H. pylori status
was followed every other using UBT or invasive tests.
The authors defined a recurrent positive H. pylori diagnosis within the first year
as “reappearance”. The rate was calculated at 1.7% for the EBMT group and
3.3% for the MEA group.
A recurrent positive test for H. pylori in the further follow-up was defined as
reinfection. The mean duration of Follow-up was 31.9 months for EBMT and 30.4
months for MEA regimen.
11.9% of the patients in the EBMT group were tested positive and 16.54% in the
MEA group.
Only 3-1 patients were followed for the period of 7 years. Therefore a really
long-term analysis is impossible.
Major remarks
Though missing deeper experience in the field of H. pylori transmission and the
nature of possible re-infection, it seems unlikely that a positive H. pylori test in
the follow-up of approximately 30 months is a true re-infection rather. Therefore it
would be worth to re-edit the manuscript to entitle “recurrent” H. pylori infection.
40% of the patients were included with gastric cancer. It needs to be stated if
these patients were in advanced tumor stages and were probably lost in follow
up. The data needs reanalyzing after exclusion of the gastric cancer cases.
Atrophic gastritis is well known to interfere with test accuracy of UBT as well as
invasive tests.
- Table 1 leeds to misunderstandings as atrophic changes and intestinal
metaplasia are much more prevalent in the MEA group which can also explain
differences between the two regimen. Data definitely needs a careful revision in
this issue.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Reviewer's report
Title:Long-term Follow up Helicobacter Pylori Reinfection Rate After
Second-Line Treatment: Bismuth-Containing Quadruple Therapy versus
Moxifloxacin-Based Triple Therapy
Version: 2Date:14 June 2013
Reviewer: Arne Kandulski
Reviewer's report:
SUMMARY
This is a prospective trial that randomized patients after failed first line H. pylori
eradication to receive either bismuth containing quadruple therapy (EBMT) or
moxifloxacin-based second line regimen (MEA).
After initial successful eradication within the first year, patients´ H. pylori status
was followed every other using UBT or invasive tests.
The authors defined a recurrent positive H. pylori diagnosis within the first year
as “reappearance”. The rate was calculated at 1.7% for the EBMT group and
3.3% for the MEA group.
A recurrent positive test for H. pylori in the further follow-up was defined as
reinfection. The mean duration of Follow-up was 31.9 months for EBMT and 30.4
months for MEA regimen.
11.9% of the patients in the EBMT group were tested positive and 16.54% in the
MEA group.
Only 3-1 patients were followed for the period of 7 years. Therefore a really
long-term analysis is impossible.
Major remarks
Though missing deeper experience in the field of H. pylori transmission and the
nature of possible re-infection, it seems unlikely that a positive H. pylori test in
the follow-up of approximately 30 months is a true re-infection rather. Therefore it
would be worth to re-edit the manuscript to entitle “recurrent” H. pylori infection.
40% of the patients were included with gastric cancer. It needs to be stated if
these patients were in advanced tumor stages and were probably lost in follow
up. The data needs reanalyzing after exclusion of the gastric cancer cases.
Atrophic gastritis is well known to interfere with test accuracy of UBT as well as
invasive tests.
- Table 1 leeds to misunderstandings as atrophic changes and intestinal
metaplasia are much more prevalent in the MEA group which can also explain
differences between the two regimen. Data definitely needs a careful revision in
this issue.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Please review this paper.
user
Reviewer's report
Title:Long-term Follow up Helicobacter Pylori Reinfection Rate After
Second-Line Treatment: Bismuth-Containing Quadruple Therapy versus
Moxifloxacin-Based Triple Therapy
Version: 2Date:14 June 2013
Reviewer: Arne Kandulski
Reviewer's report:
SUMMARY
This is a prospective trial that randomized patients after failed first line H. pylori
eradication to receive either bismuth containing quadruple therapy (EBMT) or
moxifloxacin-based second line regimen (MEA).
After initial successful eradication within the first year, patients´ H. pylori status
was followed every other using UBT or invasive tests.
The authors defined a recurrent positive H. pylori diagnosis within the first year
as “reappearance”. The rate was calculated at 1.7% for the EBMT group and
3.3% for the MEA group.
A recurrent positive test for H. pylori in the further follow-up was defined as
reinfection. The mean duration of Follow-up was 31.9 months for EBMT and 30.4
months for MEA regimen.
11.9% of the patients in the EBMT group were tested positive and 16.54% in the
MEA group.
Only 3-1 patients were followed for the period of 7 years. Therefore a really
long-term analysis is impossible.
Major remarks
Though missing deeper experience in the field of H. pylori transmission and the
nature of possible re-infection, it seems unlikely that a positive H. pylori test in
the follow-up of approximately 30 months is a true re-infection rather. Therefore it
would be worth to re-edit the manuscript to entitle “recurrent” H. pylori infection.
40% of the patients were included with gastric cancer. It needs to be stated if
these patients were in advanced tumor stages and were probably lost in follow
up. The data needs reanalyzing after exclusion of the gastric cancer cases.
Atrophic gastritis is well known to interfere with test accuracy of UBT as well as
invasive tests.
- Table 1 leeds to misunderstandings as atrophic changes and intestinal
metaplasia are much more prevalent in the MEA group which can also explain
differences between the two regimen. Data definitely needs a careful revision in
this issue.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
assistant